A Single-dose, Randomized, Open-label, Two-period Crossover Bioequivalence Study Comparing a Fixed-Dose Pediatric Combination of Lamivudine and Stavudine Tablet for Oral Suspension with Individual Liquid Formulations in Healthy Adult Male Volunteers

Abstract

Lamivudine (CAS 134678-17-4) is a synthetic nucleoside analogue with activity against HIV-1 and HBV. Stavudine (CAS 3056-17-5) is a synthetic thymidine nucleoside analogue, active against the human immunodeficiency virus (HIV). Lamivudine and stavudine in combination with other antiretroviral (ARV) agents are indicated for the treatment of HIV infection. As there are no suitable pediatric ARVs, adult fixed-dose ARVs are commonly used in children. This practice poses concerns about dose inaccuracy, which may lead to resistance or toxicity. A new fixed-dose combination (FDC) tablet for oral suspension, containing lamivudine 40 mg and stavudine 10 mg has been developed. An open-label, balanced, randomised, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study was conducted following administration of a fixed-dose combination of lamivudine and stavudine tablet for oral suspension (test formulation) and innovator products (reference formulations) in healthy, adult, male human subjects under fasting condition. Multiple blood samples were collected up to 36 h post dose. Plasma concentrations of lamivudine and stavudine were assayed using validated high-performance liquid chromatography with mass spectrometry analytical method. Pharmacokinetic parameters were calculated using non-compartmental analysis and bioequivalence was assessed using a mixed effect ANOVA model. The ratio of the least-square means (FDC to individual products) and 90% confidence intervals (CIs) of AUC_0–t AUC_0–∞ and C_max for lamivudine and stavudine were all within 80.00–125.00%, suggesting a similar rate and extent of ARVs exposure in the bloodstream. The FDC and individual products were equally safe and well tolerated. The current FDC of lamivudine and stavudine is expected to provide a similar efficacy/safety profile as co-administration of the individual products, a better adherence to treatment, and considerable cost savings in the treatment of HIV in children.

Key words

Antiretroviral agents - CAS 3056-17-5 - CAS 134678-17-4 - Lamivudine, fixed-dose pediatric combination with stavudine - Stavudine, fixed-dose pediatric combination with lamivudine

• References

• 1 WHO Library Cataloguing-in-Publication Data. AIDS epidemic update: Special report on HIV/AIDS. WHO/UNAIDS; 2006
• 2 World Health Organization. Antiretroviral therapy of HIV infection in infants and children: Towards universal access. Recommendations for a public health approach. WHO; 2006
• 3 Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L for the Médicins Sans Frontieres. Generic fixeddose combination antiretroviral treatment in resourcepoor settings: Multicentric observational cohort. AIDS. 2006; 20: 1163-9
• 4 Havens PL, Gibb DM for the American Academy of Pediatrics Committee on Pediatric AIDS Section on International Child Health. Increasing antiretroviral drug access for children with HIV infection. Pediatrics. 2007; 119: 838-45
• 5 O’Brien DP, Sauvageot D, Zachariah R, Humblet P for the Medicins Sans Frontieres In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS. 2006; 20: 1955-60
• 6 European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation – World Health Organization. Guideline for Good Clinical Practice [EMEA web site]. ICH Topic E6. Geneva, Switzerland: WHO; 2002
• 7 World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects; 1964
• 8 Life Insurance Company of India. Standard Height and Weight for Indian men and Women.
• 9 Center for Drug Evaluation and Research US Food and Drug Administration Guidance for industry: Bioanalytical method validation; May 2001
• 10 Guidance for Industry: Fixed Dose Combinations, Co-Packaged Drug Products, and Single-EntityVersions of Previously Approved Antiretrovirals for the Treatment of HIV U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); October 2006
• 11 Valenti WM. Expanding role of conformulations in the treatment of HIV infection: impact of fixed-dose combinations. AIDS Reads. 2004; 14 (10) 547-50
• 12 King JR, Kimberlin DW, Aldrovandi GM, Acosta EP. Antiretroviral pharmacokinetics in the pediatric population. Clin Pharmacokinet. 2002; 41: 1115-33
• 13 Industry Guidance, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products – General Considerations. Rockville (MD): Center for Drug Evaluation and Research (CDER), US FDA; Mar 2003